Rockville, Maryland - Glycotex Inc. has finalised an agreement with UK-based Advanced Medical Solutions (AMS) to study the use of GLYC-101 wound-healing treatment with polymer-based wound dressings manufactured by AMS.
The agreement covers an initial phase of testing use of GLYC-101 with the wound dressings and a potential extension into further research.
GLYC-101 is intended to stimulate and modulate the natural wound healing activities of several cell populations. It is a topical gel to be applied directly on the wound surface, typically following laser ablation, burn wounds, surgical wounds, venous ulcers and diabetic ulcers.
Clinical trials in Australia have shown promising results with chronic venous ulcers whilst US clinical trials continue on patients undergoing laser skin resurfacing.
AMS is a leading company in products for the $15 000 million global wound-care market using natural and synthetic polymer technology, including polyurethanes, for advanced wound dressings based on the moist healing principle.
In may 2008 AMS bought 49.4 percent of Corpura BV, which strengthened its position in hydrophilic polyurethane foam -- the largest and fastest growing segment of the advanced woundcare market.
AMS also has cyanoacrylate based tissue adhesives, used either for the closure of small cuts and trauma wounds through to large surgical incisions, or for protecting or sealing skin to prevent breakdown or infection.